News

NICE widens patient group for leukaemia drug

BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7369.852/a (Published 19 October 2002) Cite this as: BMJ 2002;325:852
  1. Zosia Kmietowicz
  1. Londona

    The National Institute for Clinical Excellence (NICE) has recommended that anyone with chronic myeloid leukaemia who has failed first line therapy or is in the accelerated and blast phase of the disease should have access to the signal transduction inhibitor imatinib (Glivec). This is a wider group of patients than doctors and campaigners originally …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe